The prognostic value of isolated tumor cells in bone marrow in breast cancer patients:: Evaluation of morphological categories and the number of clinically significant cells

被引:58
作者
Naume, B [1 ]
Wiedswang, G
Borgen, E
Kvalheim, G
Kåresen, R
Qvist, H
Janbu, J
Harbitz, T
Nesland, JM
机构
[1] Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway
[3] Norwegian Radium Hosp, Dept Surg, N-0310 Oslo, Norway
[4] Ullevaal Univ Hosp, Dept Surg, Oslo, Norway
[5] Baerum Hosp, Dept Surg, Oslo, Norway
[6] Aker Hosp, Dept Surg, Oslo, Norway
关键词
D O I
10.1158/1078-0432.CCR-03-0373
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose/Experimental Design: Immunocytochemical detection of isolated tumor cells (ITCs) in the bone marrow (BM) is a prognostic factor in breast cancer. However, hematopoietic cells (HCs) can occasionally be stained by the techniques used. Morphological evaluation improves the specificity of ITC detection, but optimal separation of ITCs from false-positive HCs needs to be determined. Here, predetermined morphological categories of immunocytochemically (ICC)-positive cells in the BM and the number of detected ITCs were analyzed for association with clinical outcome in 817 early-stage breast cancer patients (median 49 months of follow-up). All ICC+ cells detected were categorized into one of the following groups: (a) tumor cell (TC); (b) uninterpretable cell (UIC); (c) probable HC; or (d) HC. Results: Among the TC+ patients, 30.6% and 25.9% experienced systemic relapse (SR) and breast cancer death (BCD), respectively, as compared with 13.3% and 8.5% of patients without TCs in the BM (survival analyses: P < 0.001, log-rank). The SR and BCD rate was 19.7% and 15.8% for TC-/UIC+ patients versus 12.5% and 7.4% for TC-/UIC- patients. Survival analyses confirmed that the UIC+ group contained clinically significant cells (P = 0.018, log-rank). No difference in clinical outcome was observed, regardless of whether probable HCs or HCs were present. Analyzing the number of ITC+ cells, SR and BCD occurred in 12.4% and 7.4% of patients with 0 ITCs present, 21.3% and 18.5% of patients with 1ITC present, 19.4% and 16.7% of patients with 2 ITCs present, and 42.5% and 32.5% of patients with >= 3 ITCs present. Conclusions: Morphological categorization of ICC+ cells improves the clinical value of ITC detection in the BM. The presence of only one ITC reduces survival, and a greater number of ITCs further aggravates the prognosis.
引用
收藏
页码:3091 / 3097
页数:7
相关论文
共 25 条
[1]   Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells [J].
Borgen, E ;
Naume, B ;
Nesland, JM ;
Kvalheim, G ;
Beiske, K ;
Fodstad, O ;
Diel, I ;
Solomayer, EF ;
Theocharous, P ;
Coombes, RC ;
Smith, BM ;
Wunder, E ;
Marolleau, JP ;
Garcia, J ;
Pantel, K .
CYTOTHERAPY, 1999, 1 (05) :377-388
[2]  
Borgen E, 1998, J PATHOL, V185, P427, DOI 10.1002/(SICI)1096-9896(199808)185:4<427::AID-PATH127>3.0.CO
[3]  
2-7
[4]   Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. [J].
Braun, S ;
Pantel, K ;
Muller, P ;
Janni, W ;
Hepp, F ;
Kentenich, CRM ;
Gastroph, S ;
Wischnik, A ;
Dimpfl, T ;
Kindermann, G ;
Riethmuller, G ;
Schlimok, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (08) :525-533
[5]  
Braun S, 2001, CANCER RES, V61, P1890
[6]   PREDICTION OF EARLY RELAPSE IN PATIENTS WITH OPERABLE BREAST-CANCER BY DETECTION OF OCCULT BONE-MARROW MICROMETASTASES [J].
COTE, RJ ;
ROSEN, PP ;
LESSER, ML ;
OLD, LJ ;
OSBORNE, MP .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (10) :1749-1756
[7]   Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal [J].
Diel, IJ ;
Kaufmann, M ;
Costa, SD ;
Holle, R ;
vonMinckwitz, G ;
Solomayer, EF ;
Kaul, S ;
Bastert, G .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (22) :1652-1658
[8]   Epithelial cells in bone marrow of breast cancer patients at time of primary surgery:: Clinical outcome during long-term follow-up [J].
Gebauer, G ;
Fehm, T ;
Merkle, E ;
Beck, EP ;
Lang, N ;
Jäger, W .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3669-3674
[9]   Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors [J].
Gerber, B ;
Krause, A ;
Müller, H ;
Richter, D ;
Reimer, T ;
Makovitzky, J ;
Herrnring, C ;
Jeschke, U ;
Kundt, G ;
Friese, K .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (04) :960-971
[10]   TUMOR-CELL DETECTION IN THE BONE-MARROW OF BREAST-CANCER PATIENTS AT PRIMARY THERAPY - RESULTS OF A 3-YEAR MEDIAN FOLLOW-UP [J].
HARBECK, N ;
UNTCH, M ;
PACHE, L ;
EIERMANN, W .
BRITISH JOURNAL OF CANCER, 1994, 69 (03) :566-571